Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

Nicola Fazio, Jean Francois Martini, Adina E. Croitoru, Michael Schenker, Sherry Li, Brad Rosbrook, Kathrine Fernandez, Jiri Tomasek, Espen Thiis-Evensen, Matthew Kulke, Eric Raymond

Research output: Contribution to journalArticle

Abstract

Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.

Original languageEnglish
Pages (from-to)1997-2007
Number of pages11
JournalFuture Oncology
Volume15
Issue number17
DOIs
Publication statusPublished - Jun 2019

Keywords

  • biomarkers
  • efficacy
  • pancreatic neuroendocrine tumor
  • sunitinib
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors'. Together they form a unique fingerprint.

  • Cite this

    Fazio, N., Martini, J. F., Croitoru, A. E., Schenker, M., Li, S., Rosbrook, B., Fernandez, K., Tomasek, J., Thiis-Evensen, E., Kulke, M., & Raymond, E. (2019). Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. Future Oncology, 15(17), 1997-2007. https://doi.org/10.2217/fon-2018-0934